The only liver disease becoming more widespread in the U.S. is one driven by obesity and diabetes – NAFLD – even as other liver disorder types linked to drinking or hepatitis become less common.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Innovations in diabetes care go beyond new therapeutic classes. Pharmaceutical companies are continuing to invest in new technology to help improve diabetes treatment and patient adherence with progress ranging from artificial pancreases to smart insulin pens and pumps.
Shares of Texas-based Lexicon Pharmaceuticals shot up after the company announced positive 52-week cardiorenal data from a pooled analysis of the type 1 diabetes trials Tandem1 and Tandem2.
Novo Nordisk’s sales forecast for 2019 was raised due to growing demand for obesity products and a new injectable treatment for diabetes, which is now the company’s growth engine as insulin sales decline.
Eli Lilly and Co. beat analysts’ estimates for second-quarter 2019 profit and raised the company’s full-year earnings forecast, as higher sales of the diabetes drugs Trulicity and Basaglar offset competition for the erectile dysfunction treatment Cialis.
Sanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
French drugmaker Sanofi SA terminated a partnership with Lexicon Pharmaceuticals Inc. to develop and manufacture a drug for use with insulin in patients with type 1 and type 2 diabetes.
The FDA approved Eli Lilly’s Baqsimi (glucagon) nasal powder 3 mg to treat severe hypoglycemia in diabetics 4 years of age and older.
Abbott Laboratories plans to ramp up manufacturing capacity for the company’s lower-cost continuous glucose monitor – the FreeStyle Libre – by three to five times in the next few years, aiming to reach millions more patients worldwide.
The U.S. Food and Drug Administration declined to approve AstraZeneca Plc’s diabetes treatment Farxiga for use as a supplement to insulin in adults with a rare type of the condition.